Anti-tumor activity of CDYL2b in prostate cancer
Cancer Letters · 2025
DOI: 10.1016/j.canlet.2025.217987 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Letters, 2025. Verfasst von Ruicai Gu und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cell Biology, University of Oklahoma Health Sciences Center, Oklahoma City, OK, 73104, USA. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Jumonji Domain-Containing Histone Demethylases. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 97 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: NCI NIH HHS, NIGMS NIH HHS, National Cancer Institute.
Abstract (Originalsprache)
Prostate cancer is a leading cause of death among men, yet the molecular underpinnings of this malignancy are still not fully understood. We discovered that two histone demethylases driving prostate tumorigenesis, the JMJD2A and JMJD2B enzymes, suppressed transcription of the CDYL2 epigenetic reader gene. Bioinformatic analyses showed that low CDYL2 expression in prostate tumors was associated with more metastasis and disease recurrence as well as reduced survival. Out of the four predicted CDYL2 isoforms, all of which were capable of forming homo- and heteromers, only CDYL2b was appreciably expressed in prostate cancer cells and tightly associated with chromatin. Overexpression of CDYL2b in human DU145 and 22Rv1 prostate cancer cells decreased their growth and clonogenic activity in vitro as well as tumor expansion in nude mice, while CDYL2b downregulation stimulated LNCaP cell growth. RNA sequencing exposed that CDYL2b induced upregulation of transcription factor genes HES7, KLF17 and TBX6 and overexpression of those factors phenocopied to various degrees the anti-oncogenic effects of CDYL2b. Further JMJD2B, but not JMJD2A, robustly formed complexes with CDYL2b and antagonized CDYL2b in upregulating HES7 transcription. In conclusion, our data highlight that CDYL2b can suppress prostate tumorigenesis, while JMJD2A and JMJD2B may exert their pro-oncogenic functions in part through stifling CDYL2b transcription or CDYL2b activity. In addition, our study revealed that the developmental transcription factors TBX6 and HES7 may also suppress tumorigenesis.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Cell Biology, University of Oklahoma Health Sciences Center, Oklahoma City, OK, 73104, USA.
- College of Arts & Sciences, New York University, New York City, NY, 10003, USA.
- Department of Cell Biology, University of Oklahoma Health Sciences Center, Oklahoma City, OK, 73104, USA; Stephenson Cancer Center, Oklahoma City, OK, 73104, USA.
- Department of Pathology, University of Oklahoma Health Sciences Center, Oklahoma City, OK, 73104, USA.
- Department of Cell Biology, University of Oklahoma Health Sciences Center, Oklahoma City, OK, 73104, USA; Stephenson Cancer Center, Oklahoma City, OK, 73104, USA; Department of Pathology, University of Oklahoma Health S…
Förderung
- NCI NIH HHS
- NIGMS NIH HHS
- National Cancer Institute
- National Institutes of Health
- University of Oklahoma
- Oklahoma Tobacco Settlement Endowment Trust
- Stephenson Cancer Center
Zitieren
APA
Gu, R., Janknecht, J., Oh, S., Jiang, H., & Janknecht, R. (2025). Anti-tumor activity of CDYL2b in prostate cancer. Cancer Letters. https://doi.org/10.1016/j.canlet.2025.217987
Vancouver
Gu R, Janknecht J, Oh S, Jiang H, Janknecht R. Anti-tumor activity of CDYL2b in prostate cancer. Cancer Letters. 2025. doi:10.1016/j.canlet.2025.217987
BibTeX
@article{Gu2025,
author = {Gu, Ruicai and Janknecht, Julia and Oh, Sangphil and Jiang, Hanlin and Janknecht, Ralf},
title = {Anti-tumor activity of CDYL2b in prostate cancer},
journal = {Cancer Letters},
year = {2025},
doi = {10.1016/j.canlet.2025.217987}
}
EUVIMED